ASTER DM Q2 CONCALL; ONCOLOGY DRUG PRICE CAPS – MANAGEMENT VIEW

• Management expects price caps on selected oncology drugs to improve treatment affordability. • Potential Demand Benefit: Greater access to cancer treatment in Tier 2 and Tier 3 markets. • Current Financial Effect: No material impact reported. • Business Model: Management emphasized integrated clinical care rather than reliance on pharmacy margins

ASTER DM QUALITY CARE LTD

← Back to feed